Clinical Study

Subthalamic Nucleus Deep Brain Stimulation in Early Stage Parkinson’s Disease Is Not Associated with Increased Body Mass Index

Sarah H. Millan, Mallory L. Hacker, Maxim Turchan, Anna L. Molinari, Amanda D. Currie, and David Charles

Department of Neurology, Vanderbilt University Medical Center, 161 21st Ave S., A-0118 Medical Center North, Nashville, TN 37223-2551, USA

Correspondence should be addressed to David Charles; david.charles@vanderbilt.edu

Received 24 February 2017; Accepted 30 April 2017; Published 6 June 2017

Academic Editor: Raja Mehanna

Copyright © 2017 Sarah H. Millan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Previous studies suggest that deep brain stimulation of the subthalamic nucleus (STN-DBS) for Parkinson's disease (PD) leads to weight gain. This study analyzes changes in body mass index (BMI) in 29 subjects from a prospective, single-blind trial of DBS in early stage PD (age 50–75, Hoehn & Yahr stage II off medication, treated with antiparkinsonian medications for ≥6 months but < 4 years, and without a history of motor fluctuations, dyskinesias, or dementia). Subjects were randomized to DBS plus optimal drug therapy (DBS+ODT; n = 15) or ODT (n = 14) and followed for 24 months. Weight and height were recorded at baseline and each follow-up visit and used to calculate BMI. BMI change over two years was not different between the groups (p = 0.62, ODT = −0.89; DBS+ODT = −0.17). This study suggests that STN-DBS is not associated with weight gain in subjects with early stage PD. This finding will be tested in an upcoming FDA-approved phase III multicenter, randomized, double-blind, placebo-controlled, pivotal clinical trial evaluating DBS in early stage PD (ClinicalTrials.gov identifier NCT00282152).

1. Introduction

Deep brain stimulation of the subthalamic nucleus (STN-DBS) is an FDA-approved adjunctive treatment for Parkinson’s disease (PD) when symptoms are no longer adequately controlled by medications. DBS therapy is demonstrated to significantly improve motor symptoms and quality of life for PD patients. Despite its clinical success, isolated studies suggest that STN-DBS is associated with postoperative weight gain and increased body mass index (BMI) [1]. While average weight gain after STN-DBS is reported as a 12.8% increase from preoperative body weight [2], the most significant weight gain typically occurs within the first few months after surgery (8.4% BMI increase [3]), with gradual increases thereafter [1]. These reports of weight gain following STN-DBS are concerning because of the implications for this effective PD therapy leading to additional health complications such as obesity and/or diabetes [4].

STN-DBS is a potent therapy that treats many features of PD that cause weight loss as PD progresses (e.g., dyskinesias and other motor fluctuations and side effects of medical therapy, such as nausea and loss of appetite [5]). For nearly 20 years, DBS has been indicated for advanced stage PD (average disease duration of 10.8 years [6]); this PD patient population has prolonged exposure to the negative effects of the disease progression as well as medication-associated complications leading to considerable weight loss [7]. Therefore, it is not currently clear whether the postoperative weight gain previously reported is due to active STN stimulation or is a consequence of the typical postoperative reduction in medication need and/or the general benefits for PD secondary to DBS therapy.

Vanderbilt University completed a pilot safety and tolerability clinical trial testing STN-DBS in early stage PD (NCT#00282152) [8]. This study offers a unique cohort to evaluate potential postsurgical changes in BMI in early stage...
2. Parkinson’s Disease

0.5
0
−0.5
−1
−1.5
−2
Mean change in BMI from baseline
0 6 12 18 24
Months
ODT
DBS+ODT
All subjects

0.5
0
−0.5
−1
−1.5
−2
Mean change in BMI from baseline
0 6 12 18 24
Months
ODT
DBS+ODT
Excluding outlier

Figure 1: Body mass index change from baseline. (a) Average change in BMI from baseline at 6, 12, 18, and 24 months (± SEM). ODT \( n = 14 \), DBS+ODT \( n = 15 \). (b) One subject experienced significant weight loss (BMI decreased by 12 points from baseline to 24 months) and was excluded from this secondary analysis. ODT, \( n = 13 \); DBS+ODT, \( n = 15 \).

PD patients not yet experiencing many of the negative effects related to PD progression. Here, we investigated changes in BMI in the only prospective, randomized clinical trial of STN-DBS in very early stage PD.

2. Materials and Methods

Thirty subjects with early stage PD enrolled in the pilot clinical trial. The study was approved by the Vanderbilt University Institutional Review Board (IRB#040797) and the FDA (IDE#G050016). Subjects age 50 to 75 were eligible for enrollment into the study if they were diagnosed with idiopathic PD, treated with medications for more than six months and less than four years, Hoehn & Yahr stage II off medication, and without any history of motor fluctuations or dyskinesias [8–10]. Subjects were excluded if they had any major psychiatric illness, previous brain injury or operative intervention, or contraindications to surgery. A multiphased informed consent process ensured subjects’ understanding of the study [11].

Subjects were randomized to receive DBS plus optimal drug therapy (DBS+ODT \( n = 15 \)) or ODT alone \( (n = 14) \); one subject dropped out after baseline due to family and career-related circumstances). Subjects’ heights and weights were recorded every six months at each week-long Clinical Research Center (CRC) study visit.

BMI was calculated at each visit using the height and weight collected on day one of the week-long antiparkinsonian medication and stimulation washout. Mean BMI for each group at baseline, 6, 12, 18, and 24 months was calculated (Figure 1). All within- and between-group comparisons were carried out with nonparametric \( t \)-tests, Wilcoxon Signed Rank test, and Mann-Whitney \( U \) test, respectively. Data are reported as mean ± standard deviation (SD) unless otherwise indicated.

3. Results

There was no significant difference in average BMI at baseline between the ODT (29.6 ± 4.2) and DBS+ODT groups (32.3 ± 5.7; Table 1; \( p = 0.25 \)). All but one of the subjects in the pilot trial were overweight or obese at baseline (97%, 28/29 with BMI ≥ 25; Table 1).

Over the two-year study period, BMI change for the DBS+ODT group was not significant (\( p = 0.63 \); Figure 1). Although there was a reduction in average BMI in the ODT group over the two-year period, it was not a significant change from baseline to 24 months (\( p = 0.75 \)). Additionally, the between-group difference in change in BMI score at 24 months was not significant (\( p = 0.62 \)).

There was no BMI change in patients treated with STN-DBS from baseline to the first follow-up visit at 6 months (\( p = 0.65 \); Figure 1(a)) (prior studies reported the most rapid weight change after the first few months following surgery [4]). One subject in the ODT group experienced a gastrointestinal disorder unrelated to the study, which led to dramatic weight loss over the course of the trial (BMI was reduced by 32.6% from baseline to 24 months). A secondary analysis, conducted with this subject excluded, demonstrated that the slightly lower change in BMI for the ODT group compared to the DBS+ODT group was driven by this subject’s extreme weight loss (Figure 1(b)).

4. Discussion

These results suggest that STN-DBS is not associated with weight gain in early stage Parkinson’s disease. There was minimal change in BMI for the DBS+ODT group over two years (average BMI reduction = −0.17 ± 2.3). Although the BMI for the ODT group decreased slightly over two years (average BMI reduction = −0.89 ± 3.6), this change did not reach
Table 1: Characteristics at baseline.\(^a\)

| Characteristic                  | ODT (\(n = 14\)) | DBS + ODT (\(n = 15\)) |
|---------------------------------|-------------------|-------------------------|
| Gender                          |                   |                         |
| Male                            | 12                | 14                      |
| Female                          | 2                 | 1                       |
| Age (years)                     |                   |                         |
| Mean                            | 60 ± 7.0          | 60 ± 6.8                |
| Range                           | 51–69             | 52–74                   |
| Baseline medicine use           |                   |                         |
| Mean duration (years)           | 2.1 ± 1.1         | 2.2 ± 1.4               |
| Mean L-dopa equivalents (mg/day)| 569 ± 389         | 451 ± 304               |
| BMI category                    |                   |                         |
| Healthy (18.5 < BMI ≤ 24.9)     | 1                 | 0                       |
| Overweight (24.9 < BMI < 30)    | 7                 | 7                       |
| Obese (BMI ≥ 30)                | 6                 | 8                       |
| BMI (kg/m\(^2\))               | 29.7 ± 4.3        | 32.3 ± 5.7              |

\(^a\)Modified Table 1 from [10]. Mean ± SD.

significance (\(p = 0.75\)) and was largely driven by one patient who experienced dramatic weight loss from a gastrointestinal disorder unrelated to the study (Figure 1(b)). These findings suggest that weight gain previously observed in advanced PD patients [1] may not be due to STN stimulation but instead may result from the magnitude of symptom improvement that DBS provides in patients with a more advanced stage of PD.

It is well known that many PD patients experience weight loss with disease progression, and reduced BMI is correlated with increased disease severity [12]. There are many features of advanced PD that likely contribute to weight loss, including increased muscle rigidity, levodopa-induced dyskinesia with increased energy expenditure, and/or depression [5, 7]. Therefore, the great degree of improvement that advanced PD patients experience after STN-DBS therapy more likely explains the weight gain observed in previous isolated studies.

Here, we analyzed an early stage cohort not yet suffering from disabling features of PD that can lead to weight loss, and there was no significant change in BMI after STN-DBS for early stage PD patients. Because this study was open-label, it is possible that BMI changes were influenced by the subjects' awareness of their treatment allocation. Limitations for this study also include the study's small sample size and gender imbalance. It is also important to note that a majority of subjects were overweight or obese at baseline (28/29, Table 1).

Despite its superior clinical benefit over medications alone, one of the perceived drawbacks of STN-DBS therapy in advanced PD is its stimulation-associated weight gain [1]. This weight gain is likely due to a variety of factors including postoperative decreased energy expenditure [1] and dosage reduction in PD medications [2]. Since symptoms are typically mild in early stage PD, difference in pre- and postoperative energy expenditure is not expected to change as much as with advanced stage PD.

5. Conclusion

These results suggest that STN-DBS does not cause increased BMI in early stage PD. More study is needed to confirm these findings and the FDA has approved a phase III multicenter, randomized, double-blind, placebo-controlled, pivotal clinical trial evaluating DBS in early stage PD.

Disclosure

Medtronic representatives did not take part in data collection, management, analysis, or interpretation of the data or in preparation, review, or approval of the manuscript.

Conflicts of Interest

Vanderbilt University receives income from grants or contracts with Allergan, Intec, Ipsen, Lundbeck, Merz, Medtronic, and US WorldMeds for research or educational programs led by Dr. Charles. Dr. Charles receives income from Allergan, Alliance for Patient Access, Ipsen, and Medtronic for consulting or education programs. There are no conflicts of interest for Sarah H. Millan, Mallory L. Hacker, Maxim Turchan, Anna L. Molinari, and Amanda D. Currie.

Acknowledgments

The authors thank their study coordinator, Odessa Lankford, for her dedication and commitment to the trial. Research reported in this publication was supported by Medtronic, Inc., by Vanderbilt CTSA Grant ULTR000445 from the National Center for Advancing Translational Sciences (NCATS), by NCATS/NIH award ULTR000011, by NIH R01 EB006136, by private donations, and by The Michael J. Fox Foundation for Parkinson's Research.
References

[1] M. Barichella, A. M. Marczewska, C. Mariani, A. Landi, A. Vairo, and G. Pezzoli, “Body weight gain rate in patients with Parkinson’s disease and deep brain stimulation,” *Movement Disorders*, vol. 18, no. 11, pp. 1337–1340, 2003.

[2] E. Moro, M. Scerrati, L. M. A. Romito, R. Roselli, P. Tonali, and A. Albanese, “Chronic subthalamic nucleus stimulation reduces medication requirements in Parkinson’s disease,” *Neurology*, vol. 53, no. 1, pp. 85–90, 1999.

[3] P. Sauleau, E. Leray, T. Rouaud et al., “Comparison of weight gain and energy intake after subthalamic versus pallidal stimulation in Parkinson’s disease,” *Movement Disorders*, vol. 24, no. 14, pp. 2149–2155, 2009.

[4] I. Rieu, P. Derost, M. Ulla et al., “Body weight gain and deep brain stimulation,” *Journal of the Neurological Sciences*, vol. 310, no. 1-2, pp. 267–270, 2011.

[5] C. G. Bachmann and C. Trenkwalde, “Body weight in patients with Parkinson’s disease,” *Journal of the Neurological Sciences*, vol. 310, no. 1-2, pp. 267–270, 2011.

[6] F. M. Weaver and K. Follett, “Bilateral deep brain stimulation vs best medical therapy for patients with advanced Parkinson disease: a randomized controlled trial,” *Journal of the American Medical Association*, vol. 301, no. 1, pp. 63–73, 2009.

[7] K. Kashihara, “Weight loss in Parkinson’s disease,” *Neurology*, vol. 253, no. 7, pp. VII/38–VII/41, 2006.

[8] D. Charles, P. E. Konrad, J. S. Neimat et al., “Subthalamic nucleus deep brain stimulation in early stage Parkinson’s disease,” *Parkinsonism and Related Disorders*, vol. 20, no. 7, pp. 731–737, 2014.

[9] D. Charles, C. Tolleson, T. L. Davis et al., “Pilot study assessing the feasibility of applying bilateral subthalamic nucleus deep brain stimulation in very early stage Parkinson’s disease: study design and rationale,” *Journal of Parkinson’s Disease*, vol. 2, no. 3, pp. 215–223, 2012.

[10] P. D. Charles, R. M. Dolhun, C. E. Gill et al., “Deep brain stimulation in early Parkinson’s disease: enrollment experience from a pilot trial,” *Parkinsonism and Related Disorders*, vol. 18, no. 3, pp. 268–273, 2012.

[11] S. G. Finder, M. J. Bliton, C. E. Gill, T. L. Davis, P. E. Konrad, and P. D. Charles, “Potential subjects’ responses to an ethics questionnaire in a Phase I study of deep brain stimulation in early Parkinson’s disease,” *Journal of Clinical Ethics*, vol. 23, no. 3, pp. 207–216, 2012.

[12] M. A. Van der Marck, H. C. Dicke, E. Y. Uc et al., “Body mass index in Parkinson’s disease: a meta-analysis,” *Parkinsonism and Related Disorders*, vol. 18, no. 3, pp. 263–267, 2012.